文献速递胰腺与胆道疾病

丁丙诺啡对比双氯芬酸用于急性胰腺炎疼痛缓解:双盲随机对照试验

Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-11-03

本研究为双盲随机对照试验,将48例急性胰腺炎患者随机分为静脉双氯芬酸组和静脉丁丙诺啡组,比较救援芬太尼用量。丁丙诺啡组救援芬太尼总量显著低于双氯芬酸组,无痛间期更长,VAS评分下降更明显,两组不良事件相似。

要点

  • 丁丙诺啡组救援芬太尼总量中位数130μg(IQR 80-255)显著低于双氯芬酸组520μg(IQR 380-1065),P<.001。
  • 丁丙诺啡组总需求次数中位数8次(IQR 4-15)显著低于双氯芬酸组32次(IQR 21-69),P<.001。
  • 丁丙诺啡组无痛间期20小时显著长于双氯芬酸组4小时,P<.001,且24、48、72小时VAS评分下降更明显。

核心结论

  • 与双氯芬酸相比,丁丙诺啡在急性胰腺炎患者疼痛管理中似乎更有效且同样安全,在中重度/重度胰腺炎亚组中亦如此。

研究设计与样本

  • 双盲随机对照试验,48例急性胰腺炎患者随机分为静脉双氯芬酸组(24例)和静脉丁丙诺啡组(24例),芬太尼作为救援镇痛经患者自控镇痛泵给药。

主要发现

  • 丁丙诺啡组救援芬太尼总量中位数130μg(IQR 80-255)显著低于双氯芬酸组520μg(IQR 380-1065),P<.001。
  • 丁丙诺啡组总需求次数中位数8次(IQR 4-15)显著低于双氯芬酸组32次(IQR 21-69),P<.001。
  • 丁丙诺啡组无痛间期20小时显著长于双氯芬酸组4小时,P<.001。
  • 丁丙诺啡组在24、48、72小时VAS评分下降幅度大于双氯芬酸组。
  • 上述发现在中重度/重度胰腺炎亚组中得到证实,两组不良事件特征相似。

关键数值与推荐

  • 主要结局为救援芬太尼需求量差异;次要结局包括救援芬太尼有效及无效需求次数、无痛间期、VAS评分下降、不良事件及器官衰竭发生。

临床怎么用

  • 原文结论认为丁丙诺啡似乎比双氯芬酸更有效且同样安全,可用于急性胰腺炎患者疼痛管理,包括中重度或重度胰腺炎亚组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although both nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids are used for analgesia in acute pancreatitis (AP), the analgesic of choice is not known. We compared buprenorphine, an opioid, and diclofenac, an NSAID, for analgesia in AP. METHODS: In a double-blind randomized controlled trial, AP patients were randomized to receive intravenous diclofenac or intravenous buprenorphine. Fentanyl was used as rescue analgesia, delivered through a patient-controlled analgesia pump. Primary outcome was the difference in the dose of rescue fentanyl required. Secondary outcomes were the number of effective and ineffective demands of rescue fentanyl, pain-free interval, reduction in visual analogue scale (VAS) score, adverse events, and organ failure development. RESULTS: Twenty-four patients were randomized to diclofenac and 24 to buprenorphine. The 2 groups were matched at baseline. The total amount of rescue fentanyl required was significantly lower in the buprenorphine group:130 μg, interquartile range (IQR), 80-255 vs 520 μg, IQR, 380-1065 (P < .001). The number of total demands was 32 (IQR, 21-69) in the diclofenac arm vs 8 (IQR, 4-15) in the buprenorphine arm (P < .001). The buprenorphine group had more prolonged pain-free interval (20 vs 4 hours; P < .001), with greater reduction in the VAS score at 24, 48, and 72 hours compared with the diclofenac group. These findings were confirmed in the subgroup of moderately severe/severe pancreatitis. Adverse events profile was similar in the 2 groups. CONCLUSIONS: Compared with diclofenac, buprenorphine appears to be more effective and equally safe for pain management in AP patients, even in the subcohort of moderately severe or severe pancreatitis (Trial Registration number: CTRI/2020/07/026914).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Saini M, Samanta J, Kumar A, et al. Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2023. PMID: 37924855. doi:10.1016/j.cgh.2023.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。